CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 130 enrolled
Drug / intervention
HAFS Supplementation +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06774742
NCT06774742N/ACompleted

Evaluation of the Effects of a Dietary Supplement Containing a Full Range of Hyaluronic Acids in Healthy Female Subjects With Dry Facial Skin and Lips

TS Biotech - Shandong Tiansheng Biotechnology Co., Ltd·interventional·Posted Jan 14, 2025·Updated Sep 24, 2025

In Brief

A clinical study evaluating HAFS Supplementation and Placebo for Skin Quality and 2 related conditions. Completed, enrolled 130 participants across 1 site.

Detailed Summary

This is a single center, double-blind, randomized, placebo-controlled study, performed on two parallel groups. A total of 130 adult female subjects meeting specific inclusion/exclusion criteria will be included in order to have 120 subjects who complete the study at Day 98/Week 14. Subjects will be randomly assigned to either the FS-HA oral supplementation group (60 subjects) or the placebo group (60 subjects). The subjects should agree to attend a total of five (5) visits as follows: * a screening visit within 21 days prior to Day 1 (from Day -22 to Day -1); * a baseline visit (Day 1); * two (2) intermediate visits (Day 29 and Day 84); * a follow-up and end-of- study visit on Day 98. The primary objective of this study is to evaluate the effects of an oral supplementation containing a FS-HA on facial skin hydration after 3 months of use, compared with Placebo. The Secondary Objective(s) will evaluate the effects of an oral supplementation containing a FS-HA compared with Placebo on: * the hydration of the lips using corneometry; * the skin quality of the face using dermatological assessments and biophysical measurements (TEWL and Mexametry); * the quality/health and beauty of the lips using dermatological assessments and biophysical measurements (Mexametry); * the volume of the lips using image analysis; * to assess the persistence of the effects 2 weeks after discontinuation; * to assess the subject perceived efficacy and acceptability (subject self-assessment); * to evaluate the safety of the study products.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedJan 14, 2025
Enrollment StartJan 2, 2025
Primary CompletionJul 3, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 1.5 years ago

Interventions

HAFS Supplementationdietary

1 capsule of HAFS per day

Placebodietary

1 capsule of placebo per day